Enveric Biosciences Signed Two Non-binding Term Sheets With An Undisclosed Biotechnology Company To Pursue The Out-licensing Of Cannabinoid-COX-2 Conjugate Compounds For Pharmaceutical And Non-pharmaceutical Applications For Joint Diseases For $82M
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has signed two non-binding term sheets with an undisclosed biotechnology company for the out-licensing of cannabinoid-COX-2 conjugate compounds, aimed at pharmaceutical and non-pharmaceutical applications for joint diseases.
March 19, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has entered into agreements for the out-licensing of cannabinoid-COX-2 conjugate compounds, targeting applications in joint diseases.
The signing of non-binding term sheets for the out-licensing of cannabinoid-COX-2 conjugate compounds indicates a strategic move by Enveric Biosciences to capitalize on its research and development in the pharmaceutical and non-pharmaceutical sectors. This could potentially open new revenue streams and partnerships, positively impacting the company's growth and valuation in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90